Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(10 years from now) | |
US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(10 years from now) | |
US12049628 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) | |
US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(11 months from now) | |
US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(1 year, 9 months from now) | |
US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(4 years from now) | |
USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(5 years from now) | |
US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(5 years from now) | |
US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(11 months from now) | |
US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(11 months from now) | |
US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(1 year, 11 months from now) | |
US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
US12036219 | MELINTA | Methods of treating infections in overweight and obese patients using antibiotics |
Jun, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
New Indication(I-815) | Oct 24, 2022 |
Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...
Dosage: TABLET; POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11845867 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Nov, 2036
(12 years from now) | |
US11499050 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 08, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 08 July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(6 years ago) | |
USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(5 months ago) | |
US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6002008 | PF PRISM CV | Substituted 3-cyano quinolines |
Mar, 2018
(6 years ago) | |
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(4 days from now) | |
US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 2 months from now) | |
US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(1 year, 2 months from now) | |
US7919625 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(1 year, 8 months from now) | |
US7417148 (Pediatric) | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Jun, 2026
(1 year, 8 months from now) | |
US7767678 (Pediatric) | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
May, 2027
(2 years from now) | |
US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(9 years from now) | |
US11103497 (Pediatric) | PF PRISM CV | Treatment of imatinib resistant leukemia |
Aug, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
New Indication(I-759) | Dec 19, 2020 |
Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
New Indication(I-923) | Sep 26, 2026 |
New Product(NP) | Sep 26, 2026 |
Pediatric Exclusivity(PED) | Mar 26, 2027 |
Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating a neoplasm; A method of treating patients 1 year of age and older with chronic phase ph+ cml, newly-diagnosed or resistant or intolerant to prior therapy; A method for treating a ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) | |
USRE50050 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-297) | Jun 15, 2026 |
New Chemical Entity Exclusivity(NCE) | Apr 28, 2027 |
Orphan Drug Exclusivity(ODE-398) | Apr 28, 2029 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 28 April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Feb 09, 2026 |
New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(3 years from now) | |
US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11590246 | GUERBET | Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process |
Jan, 2040
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(11 months from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(4 years ago) | |
US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(5 months ago) | |
US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(6 months from now) | |
US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(6 months from now) | |
US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(8 months from now) | |
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 4 days from now) | |
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 4 days from now) | |
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 2 months from now) | |
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 5 months from now) | |
US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(1 year, 10 months from now) | |
US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(1 year, 10 months from now) | |
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(2 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
US8221786 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US8716251 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
US7851502 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Feb, 2029
(4 years from now) | |
US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(5 years from now) | |
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) | |
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | |
US8721615 (Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(5 years from now) | |
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(6 years from now) | |
US11826376 | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jul, 2039
(14 years from now) | |
US11826376 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
Jan, 2040
(15 years from now) | |
US11903955 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(15 years from now) | |
US11903955 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) | |
US10973836 (Pediatric) | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Sep, 2040
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-157) | Mar 11, 2018 |
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-212) | Oct 20, 2020 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Indication(I-834) | May 05, 2023 |
New Indication(I-857) | Apr 30, 2024 |
M(M-298) | May 08, 2026 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-r...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10689377 | MIRATI THERAPS | KRas G12C inhibitors |
May, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(1 year, 15 days from now) | |
US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(1 year, 11 months from now) | |
US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7253286 (Pediatric) | EISAI INC | Nitrogen-containing aromatic derivatives |
Apr, 2026
(1 year, 6 months from now) | |
US7612208 (Pediatric) | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Mar, 2027
(2 years from now) | |
US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(2 years from now) | |
US9006256 (Pediatric) | EISAI INC | Antitumor agent for thyroid cancer |
Jan, 2028
(3 years from now) | |
US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(11 years from now) | |
US11186547 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(11 years from now) | |
US10259791 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(11 years from now) | |
US10407393 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(11 years from now) | |
US11090386 (Pediatric) | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Aug, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-734) | May 13, 2019 |
New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
New Indication(I-787) | Aug 15, 2021 |
Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
New Indication(I-807) | Sep 17, 2022 |
M(M-269) | Jul 21, 2024 |
New Indication(I-868) | Aug 10, 2024 |
M(M-272) | Dec 19, 2024 |
Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
M(M-14) | Apr 03, 2027 |
Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(8 years from now) | |
US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(6 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(8 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(7 years ago) | |
USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(2 years ago) | |
US7994364 (Pediatric) | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Dec, 2025
(1 year, 2 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
New Patient Population(NPP) | Jul 03, 2026 |
Pediatric Exclusivity(PED) | Jan 03, 2027 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 03 January, 2026
Market Authorisation Date: 20 November, 2008
Treatment: Management of moderate to severe acute pain; Relief of moderate to severe acute pain
Dosage: TABLET; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(7 months ago) | |
US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(11 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7989474 | BOEHRINGER INGELHEIM | Use of Lck inhibitors for treatment of immunologic diseases |
Apr, 2024
(6 months ago) | |
US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(1 year, 2 months from now) | |
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(1 year, 5 months from now) | |
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(1 year, 8 months from now) | |
US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(4 years from now) | |
US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(4 years from now) | |
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(5 years from now) | |
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
New Indication(I-805) | Sep 06, 2022 |
New Indication(I-825) | Mar 09, 2023 |
Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8648097 | VISIOX PHARMA | Pyridylaminoacetic acid compound |
Oct, 2029
(5 years from now) | |
US10774072 | VISIOX PHARMA | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685986 | VISIOX PHARMA | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(5 years from now) | |
US10702511 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10765750 | VISIOX PHARMA | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11793798 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
USRE48183 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US9415038 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10179127 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11197849 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11666563 | VISIOX PHARMA | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(5 years ago) | |
US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(9 months ago) | |
US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(1 year, 6 months ago) | |
US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(1 year, 6 months ago) | |
US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 6 months ago) | |
US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 6 months ago) | |
US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 6 months ago) | |
US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(1 year, 6 months ago) | |
US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(1 year, 6 months ago) | |
US7427638 (Pediatric) | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Aug, 2028
(3 years from now) | |
US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(9 years from now) | |
US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(9 years from now) | |
US10092541 (Pediatric) | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
Nov, 2034
(10 years from now) | |
US9872854 (Pediatric) | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
Nov, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-694) | Sep 23, 2017 |
New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
New Indication(I-803) | Jul 19, 2022 |
M(M-257) | Apr 10, 2023 |
New Indication(I-884) | Dec 20, 2024 |
Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
M(M-299) | Jul 20, 2026 |
Pediatric Exclusivity(PED) | Jan 20, 2027 |
New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of adult patients wi...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10406240 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
US11318121 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
US10398791 | NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11951190 | NOVARTIS | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
Nov, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8828427 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5635517 | BRISTOL | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul, 2016
(8 years ago) | |
US6476052 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(8 years ago) | |
US5653517 | BRISTOL | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul, 2016
(8 years ago) | |
US8158653 | BRISTOL | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug, 2016
(8 years ago) | |
US6316471 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Aug, 2016
(8 years ago) | |
US8589188 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
US8204763 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
US6561976 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
US6045501 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
US6908432 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(6 years ago) | |
US8315886 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6561977 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US8626531 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6755784 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6315720 | BRISTOL | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
US8735428 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(1 year, 4 months ago) | |
US8673939 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(1 year, 4 months ago) | |
US8735428 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(10 months ago) | |
US8673939 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(10 months ago) | |
US8198262 | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(8 months from now) | |
US8198262 (Pediatric) | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(1 year, 2 months from now) | |
US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(5 years from now) | |
US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(5 years from now) | |
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
US8828427 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
New Indication(I-707) | Apr 23, 2018 |
Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
M(M-14) | Nov 20, 2023 |
Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
Pediatric Exclusivity(PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide while ...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE49582 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(6 years from now) | |
US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(6 years from now) | |
US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(7 years from now) | |
US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(7 years from now) | |
US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(7 years from now) | |
US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(8 years from now) | |
US11793806 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Apr, 2033
(8 years from now) | |
US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(14 years from now) | |
US11878049 | AGIOS PHARMS INC | Mitapivat therapy and modulators of cytochrome P450 |
Jul, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the t...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(8 years from now) | |
US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
US11583542 | AMYLYX | Compositions of bile acids and phenylbutyrate compounds |
Jul, 2040
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(14 years from now) | |
US12053463 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(10 years from now) | |
US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(14 years from now) | |
US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(14 years from now) | |
US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(14 years from now) | |
US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(14 years from now) | |
US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(14 years from now) | |
US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(14 years from now) | |
US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10682338 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US11324721 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(10 years from now) | |
US10335390 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US10849884 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US10857133 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US11000508 | LUPIN | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(10 years from now) | |
US11000507 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US11020377 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) | |
US11602522 | LUPIN | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(10 years from now) | |
US11684607 | LUPIN | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
New Indication(I-866) | Jun 30, 2024 |
New Patient Population(NPP) | Jan 26, 2025 |
Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 15 September, 2017
Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older
Dosage: GRANULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(9 years from now) | |
US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(13 years from now) | |
US11944611 | GILEAD SCIENCES INC | Capsid inhibitors for the treatment of HIV |
Jun, 2041
(16 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
US11944611 | GILEAD SCIENCES INC | Capsid inhibitors for the treatment of HIV |
Jun, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: SOLUTION; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7144884 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Jun, 2026
(1 year, 8 months from now) | |
US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8476279 | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Oct, 2022
(2 years ago) | |
US7144884 (Pediatric) | TAKEDA PHARMS USA | Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
Dec, 2026
(2 years from now) | |
US9125910 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US9125909 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US9125908 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US9227946 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US8969355 | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US9861630 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(2 years from now) | |
US11458134 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US9125910 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US9125908 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US9125909 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US9861630 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US8969355 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US9227946 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment |
Dec, 2027
(3 years from now) | |
US8722684 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2031
(7 years from now) | |
US9278096 | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Mar, 2032
(7 years from now) | |
US9278096 (Pediatric) | TAKEDA PHARMS USA | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
Sep, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
M(M-227) | May 02, 2021 |
M(M-234) | Oct 19, 2021 |
M(M-267) | Nov 13, 2023 |
M(M-187) | Jan 22, 2024 |
M(M-232) | Aug 23, 2026 |
Pediatric Exclusivity(PED) | Feb 23, 2027 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: Method of treating an affective disorder such as depression; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Method of treating depressi...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(4 years from now) | |
US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(4 years from now) | |
US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(4 years from now) | |
US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(6 years from now) | |
US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(7 years from now) | |
US9724360 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
US9949994 | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Oct, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8318682 (Pediatric) | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(5 years from now) | |
USRE46762 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(5 years from now) | |
US8008264 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Mar, 2030
(5 years from now) | |
US10065958 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Mar, 2032
(7 years from now) | |
US11492353 (Pediatric) | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Jun, 2032
(7 years from now) | |
US9724360 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(11 years from now) | |
US9949994 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Filoviridae virus infections |
Apr, 2036
(11 years from now) | |
US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(11 years from now) | |
US11007208 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
US11382926 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
US10695361 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
US11266681 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
US10675296 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
US11975017 | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jul, 2038
(13 years from now) | |
US11266681 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(14 years from now) | |
US11975017 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(14 years from now) | |
US10675296 (Pediatric) | GILEAD SCIENCES INC | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
Jan, 2039
(14 years from now) | |
US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(16 years from now) | |
US11903953 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(16 years from now) | |
US11975012 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(16 years from now) | |
US11491169 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(17 years from now) | |
US11903953 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(17 years from now) | |
US11975012 (Pediatric) | GILEAD SCIENCES INC | Remdesivir treatment methods |
Nov, 2041
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-183) | Jan 21, 2025 |
New Patient Population(NPP) | Apr 25, 2025 |
New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
M(M-301) | Jul 13, 2026 |
Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (weighing at least 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitali...
Dosage: POWDER; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8153632 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
Jan, 2029
(4 years from now) | |
US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 01, 2026 |
New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
New Indication(I-948) | Jul 17, 2027 |
Drugs and Companies using VONOPRAZAN FUMARATE ingredient
NCE-1 date: 03 May, 2026
Market Authorisation Date: 01 November, 2023
Treatment: NA
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10647649 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(14 years from now) | |
US11597692 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458108 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US10426743 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US11612573 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US11622945 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US10195160 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US11617724 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(11 years from now) | |
US11590088 | DERMAVANT SCI | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 23 May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10583205 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Feb, 2035
(10 years from now) | |
US11052161 | POLAREAN | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
Dec, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 23, 2027 |
Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient
NCE-1 date: 23 December, 2026
Market Authorisation Date: 23 December, 2022
Treatment: NA
Dosage: GAS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(11 months from now) | |
US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(4 years ago) | |
US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(4 years ago) | |
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 5 months from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(2 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(5 years from now) | |
US7919598 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2030
(5 years from now) | |
US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(6 years from now) | |
US8685934 (Pediatric) | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
Nov, 2030
(6 years from now) | |
US9616028 (Pediatric) | ASTRAZENECA AB | Bilayer tablet formulations |
May, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
M(M-238) | Feb 22, 2022 |
New Indication(I-841) | Oct 18, 2022 |
New Patient Population(NPP) | Jun 12, 2027 |
Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) | |
US11918623 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(6 years from now) | |
US11918623 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) | |
US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Nov 08, 2026 |
New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(2 years from now) | |
US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION